Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
Highlights:
- Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes
- Positive outcome is an important milestone that enables Neuren to proceed with IND applications for FDA clearance to start the trials
- Subject to...
Read more: Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
